» Articles » PMID: 15996932

Prognostic Factors Identifiable at the Time of Onset of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation

Overview
Journal Haematologica
Specialty Hematology
Date 2005 Jul 6
PMID 15996932
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation.

Design And Methods: In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation.

Results: Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients.

Interpretation And Conclusions: Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.

Citing Articles

α-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Magenau J, Goldstein S, Peltier D, Soiffer R, Braun T, Pawarode A Blood. 2018; 131(12):1372-1379.

PMID: 29437593 PMC: 5865235. DOI: 10.1182/blood-2017-11-815746.


Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients.

Dai Z, Liu J, Zhang W, Cao X, Zhang Y, Dai Z Mol Clin Oncol. 2016; 4(4):667-671.

PMID: 27073687 PMC: 4812520. DOI: 10.3892/mco.2016.765.


A risk-adapted approach to acute GVHD treatment: are we there yet?.

Holtan S, MacMillan M Bone Marrow Transplant. 2015; 51(2):172-5.

PMID: 26551780 DOI: 10.1038/bmt.2015.261.


Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.

Bayraktar U, Milton D, Guindani M, Rondon G, Chen J, Al-Atrash G Biol Blood Marrow Transplant. 2015; 22(3):505-13.

PMID: 26524730 PMC: 7107718. DOI: 10.1016/j.bbmt.2015.10.020.


Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Alam N, Xu W, Atenafu E, Uhm J, Seftel M, Gupta V Bone Marrow Transplant. 2015; 50(5):734-42.

PMID: 25774595 DOI: 10.1038/bmt.2015.19.